"Bio-Implants Market by Products (Cardiovascular, Spine, Orthopedics & Trauma, Dental, Drug & Other Implants), Mode of Administration (Surgical & Injectable/Non-Surgical), By Origin (Allograft, Autograft, Xenograft, Synthetic), and by Material (Ceramics, Biomaterial, Alloys, & Polymers) - Competitive Landscape, Opportunities and Global Forecasts (2012-2017)"
Bio-implants can be defined as prostheses used to regularize physiological functions. They are made up of biosynthetic materials like collagen, and tissue-engineered products like artificial skin or tissues. Most bioengineered products like cardiac pacemakers and orthopedic artificial implants are also covered under bio-implants, since they are implanted entirely in the patient's body.
Bio-implants are mostly classified at a broader level as:
According to the Centers for Disease Control and Prevention (CDC), there were 40 million people aged 65 and above in the United States in 2010, accounting for 13% of the total population. The older population in 2030 is projected to be twice as large as in 2000, growing from 35 million to 72 million and representing nearly 20% of the total U.S. population. This growth in aging population is expected to push the growth of the dental, reconstructive joint replacement, ophthalmic, and neuromodulation implants markets.
This report describes the growth opportunities in the global bio-implants market. It focuses on the increase in demand for technologically advanced products that may help in faster recovery and better efficacy of physiological body functions.
The global bio-implants market is estimated to be $94.1 billion in 2012 and is poised to grow at a CAGR of 7.3% from 2012 to 2017. Rise in the aging population and increase in incidences of chronic diseases like osteoarthritis, old age-related trauma, cardiovascular diseases, neuropathic disorders (Alzheimer's disease and Parkinson's), and congenital disorders and deformities is expected to trigger the growth of this market.
The major players in this market are Stryker Corporation (U.S.), Synthes (U.S.), Boston Scientific Corporation (U.S.), Biomet, Inc. (U.S.), Smith & Nephew (U.K.), Medtronic (U.S.), St. Jude Medical, Inc. (U.S.), Tornier N.V. (The Netherlands), and others.
The global bio-implants market is segmented by types, which include major segments such as orthopedic, cardiovascular, dental, ophthalmic, neurostimulation, and others, and by origin (allograft, autograft, xenograft, and synthetic). Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
The use of bio-implants to restore biological structures of the body dates back to the beginning of the 20th century. The early applications of bio-implants included replacement, repair and restoration of hard tissues such as bones, as well as soft tissues including organs, and skin. Over the century, these have evolved and are now used for not just structural revamps, but for various purposes such as for delivering drugs internally to the body and for hormone replacement. They have vast applications and also include electronic battery-operated devices, which help correct the pace of heart beats as well as send interference signals to the nervous system. Their superiority to drugs in treating certain illnesses has been acknowledged globally. Considering the continued quest for better, safer and more effective implants, dealing with diseases is expected to become easier, more cost effective and faster.
The most preferred bio-implants are those of biological origin as they are easily compatible with the body environment. However, synthetic bio-implants are also being increasingly used. Advances in tissue engineering have enabled researchers to prepare artificial prostheses having improved compatibility with the human body The various artificial materials used for preparing bio-implants include metals, ceramics, and special plastic or polymers
The overall bio-implants market is being driven by aging populations, rising incidence of diseases and conditions such as obesity, stress, changing lifestyles, increasing awareness, patient acceptance, product innovation, and increased clinical evidence to prove safety and efficacy of implants.
The global bio-implants market was valued at $94.1 billion for 2012; North America has been, and is expected to be, the largest region for this market, Europe being the second, followed by Asia. The Asian region is set to record the highest CAGR in the global bio-implants market.
The dominant players in the global bio-implants market include Medtronic, St. Jude Medical, Stryker, Boston Scientific, DePuy Synthes, C R Bard, Gore (WL) & Associates Incorporated, Abbott Laboratories, Braun (B.) Melsungen AG, Edwards Lifesciences Corporation Sorin SpA, Zimmer Holdings, Nobel Biocare, Straumann, Dentsply/Astratech, Biomet/3i, Novartis(Alcon), Bausch & Lomb, Cyberonics, Johnson & Johnson, Integra Life Sciences, and Smith & Nephew.